• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Vectibix (Panitumumab) Injection for Intravenous Infusion

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


August 2014

Summary View


Dermatologic and Soft Tissue Toxicity
  • …It could not be determined whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis)…


Postmarketing Experience

Skin and subcutaneous tissue disorders:

  • … life threatening and fatal bullous mucocutaneous disease


August 2012

Summary View 


Dermatologic Toxicity
  • Monitor patients who develop dermatologic toxicities while receiving Vectibix for the development of inflammatory or infectious sequelae…
Increased Mortality or Toxicity with Vectibix in Combination with Chemotherapy 
  • Vectibix is not indicated for use in combination with chemotherapy…       
Pulmonary Fibrosis/Interstitial Lung Disease (ILD)
  • Pulmonary fibrosis occurred in less than 1% (2/1467) of patients enrolled in clinical studies of Vectibix. Patients with a history or evidence of interstitial pneumonitis, pulmonary fibrosis, were excluded from most clinical trials…


  • As monotherapy: The incidence of binding antibodies (excluding pre-existing and transient positive patients) was 0.4% (3/717), as detected by the acid dissociation ELISA, and 3.8% (27/717) as detected by the Biacore assay… 
  • In combination with irinotecan- or oxaliplatin-based chemotherapy: The incidence of binding antibodies (excluding pre-existing positive patients) was 1% (11/1124) as detected by the acid dissociation ELISA and 0.8% (9/1123) as detected by the Biacore assay…